Consumer advocates concerned about the impact of consolidation in the generic drug industry on prices and supply have not been mollified by pharmaceutical giant Teva’s sudden decision to drop its bid...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: